SWICH
Posted - 18 minutes from now
$IOBT Does anyone know if these three majority shareholders are still invested here? I don't see any notifications to confirm.
GCPA
Posted - 7 hours ago
$IOBT I am glad they left. Now we know more about the September sell off.
Investor6
Posted - 1 day ago
smallcaps you can buy a few cents less than a dollar: $AIHS China $GAME Canada PITA Germany $GNS Singapore $ENLV Israel $IOBT Denmark
RasbInNL
Posted - 1 day ago
$IOBT any news? or just the market being the market
made006
Posted - 3 days ago
@Fvalstounge i watch it closely at the moment it seems that Wallstreet doesn't have much interest in cancer vaccine, the attention is on ADC and radiotherapy. definitely $IOBT has large market size in melanoma and lung cancer. interestingly both $IOBT and $BCTX has pivotal study result in 2h next year potentially allowing bla submission for approval .
made006
Posted - 4 days ago
@Fvalstounge would like to know why you into BCTX when there's also $IOBT which develop same medicine (cancer vaccine ) which one better according to you ?
made006
Posted - 5 days ago
$BCTX seem like Wallstreet doesn't like cancer vaccine , what happened to BCTX also happened to $IOBT which also treat a blockbuster melanoma and lung cancer . Big pharma acquisition mainly in radiotherapy and ADC
GCPA
Posted - 6 days ago
$IOBT Stonepine and Citadel out.
Notnotshort
Posted - 1 week ago
$IOBT In the checkmate 67 trial, they enrolled ~313 patients for each of the 3 arms between July 2013 and March 2014. The database lock was in February 2015. Median follow-up was 12.2-12.5 months. The last patient enrolled had 9-10 months of treatment, depending on when the soft-lock of the dabase occured. IMO the soft lock happened in November/December 2013, as that were the months where they prolly had 50% enrolled in the trial. So 12 months later gets us to November/December 2014. At the time of the DBL that is mentioned in nejm, the Nivo arm had 174 events, which are 55.5% basically the same amount we need. Compared to our trial, we had 225 patients enrolled in June 2023, which are 55% of all patients, so 55% of our patients will have 6 more months on treatment vs Checkmate 67. The first patient in Checkmate was 17/18 months on treatment, while our first patient started in May 2022. Here a model of the checkmate trial. 1/2 https://www.nejm.org/doi/suppl/10.1056/NEJMoa1504030/suppl_file/nejmoa1504030_appendix.pdf
Notnotshort
Posted - 1 week ago
$IOBT It didnt help to advertise last time, but if you have a management that is re*arded, you gotta try again what brought in 0 new investors and costs thousands of dollars. https://www.fiercebiotech.com/sponsored/vaccinating-against-cancer-cells-and-reprogramming-tumor-microenvironment-protects-them
Notnotshort
Posted - 1 week ago
$IOBT Insane that they still cant be more precise in what quarter they expect to hit the 226 events. Always freaking uncertainty with this trash management. No wonder everyone dislikes these clowns
GCPA
Posted - 1 week ago
$IOBT “As we look to the primary endpoint data readout from our Phase 3 pivotal trial in the first half of next year, we plan to be prepared to submit a Biologics License Application (BLA) to the FDA in 2025 and potentially make our first therapeutic cancer vaccine available for patients in the US with advanced melanoma in 2026.” https://finance.yahoo.com/news/io-biotech-reports-third-quarter-120500999.html
lucky9150
Posted - 1 week ago
$IOBT , out with 3k loss. Gl longs. Holded for too long. Hope all you make your money back.
GCPA
Posted - 1 week ago
$IOBT Well...
lucky9150
Posted - 1 week ago
$IOBT , piece of junk....
GCPA
Posted - 1 week ago
$IOBT Who sold 1.650.000 shares in a row?
Notnotshort
Posted - 1 week ago
$IOBT Females not only derive less benefit from immunotherapy in several cancers, especially NSCLC high PDL1 and melanoma compared to males, they also experience a much higher frequency of TRAEs compared to males. Even with chemotherapy women usually have higher TRAEs than males. Therefore you will want to have as much males as possible, because they will give higher efficacy and a better safety profile. In NSCLC females should always get a combo of anti-pd1+chemo, no matter the PDL1 status but the side effects are very hard esp. for females. I think thats why we had so many females in our trial, because the vax is supposed to add efficacy without increasing systemic toxicities. However, anti-pd1 alone is a big issue for females, so its not surprising to see many patients stopping treatment way before PD. Females even derived less benefit from Opdualag compared to males in melanoma. The males carried the trial. Now think about why SMMT had ~90% males in their Ph3 NSCLC trial.
GCPA
Posted - 1 week ago
$IOBT "Michael Ulz has given his Buy rating due to a combination of factors that highlight the promising potential of IO Biotech’s developments. A significant aspect influencing this decision is the positive updated data from the Phase 2 basket study of IO102-IO103 in combination with pembrolizumab, which showed an overall response rate of 55% in non-small cell lung cancer patients, demonstrating a clear advantage over pembrolizumab monotherapy. The progression-free survival rate of 8.1 months, with some patients exceeding 20 months, further underscores the durability of the treatment response." https://www.tipranks.com/news/blurbs/promising-potential-of-io-biotech-buy-rating-backed-by-strong-phase-2-data-and-strategic-growth-plans?mod=mw_quote_news
lucky9150
Posted - 1 week ago
$IOBT , is it good news ?
GCPA
Posted - 2 weeks ago
$IOBT The 12 months PFS rate is 48% (no more patients progresed between month 8.1 -that marks mPFS- and 12). It compares favourably with the 37'8% of Pembro alone (KEYNOTE-042).
GCPA
Posted - 2 weeks ago
$IOBT Well: - 55% unconfirmed (16 partial responses, 1 complete response), 48% confirmed overall response rate (ORR) in a PD-L1 high population of patients with NSCLC - 81% disease control rate (DCR) - No disease progression at 12 months in approximately 50% of patients - Encouraging 8.1-month median progression-free survival (PFS) - Median duration of response (DOR) not yet reached I guess PFS at 12 months compares very well with Keytruda (37'8% in KEYNOTE-42). And this are really good news for Melanoma (time works in a positive way for the combination). https://finance.yahoo.com/news/io-biotech-reports-off-shelf-150000320.html
Thestocktraderhubzee
Posted - 2 weeks ago
WATCHLIST NOV 07 2024.
$APLS Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $51
$IOBT HC Wainwright & Co. Reiterates Buy on IO Biotech, Maintains $12 Price Target
$GERN HC Wainwright & Co. Reiterates Buy on Geron, Maintains $8 Price Target
$AMZN Loop Capital Maintains Buy on Amazon.com, Raises Price Target to $275
$STKL Stephens & Co. Maintains Overweight on SunOpta, Raises Price Target to $10
Nanu108
Posted - 2 weeks ago
$IOBT I doubled today.
Notnotshort
Posted - 2 weeks ago
$IOBT Finally had some time to look in greater detail at the abstract. 2 things that are important. 1) Females generally have lower PDL1 expression in NSCLC than males. So the amount of females with 90-100% PDL1 expression will be relatively low. 2) Females generally dont get much more benefit from anti-PD1 treatment compared to chemotherapy. Even the female 90-100% PDL1 expresser do not get a lot of benefit from anti-pd1 treatment compared to males. Male 90-100% PDL1 expresser have ORR of 50-60%. This is the group that carries >50% PDL1 NSCLC trials and are responsible for the approvals basically. Females "reduce" ORR, PFS and OS. Being female is basically a negative prognostic factor in monotherapy anti-pd1 setting. Its very unusual to have 51% of females in an NSCLC trial. All the other NSCLC trials have like 15-40%. Summit only had 15% of females. https://www.esmoopen.com/article/S2059-7029(21)00212-X/fulltext
lucky9150
Posted - 2 weeks ago
$IOBT , let's pray 🙏 for outstanding data.
GCPA
Posted - 2 weeks ago
$IOBT "Although the increase in response rate is less than 10%, the potential for progression-free survival (PFS) and overall survival (OS) benefits in the future remains a key consideration for continued investment." https://www.tipranks.com/news/blurbs/io-biotech-receives-buy-rating-amid-promising-phase-2-results-and-future-potential-in-cancer-treatments?mod=mw_quote_news
lucky9150
Posted - 2 weeks ago
$IOBT , HI GCPA, if data is favorable. What will be the price action ?
lucky9150
Posted - 2 weeks ago
$IOBT, on 9th November they are presenting anything new ? Or same old data ?
GCPA
Posted - 2 weeks ago
$IOBT Here is the PFS long-term curve in KEYNOTE-042. At 6'5 months the PFS is exactly the same (50%) for both Pembro and chemo. It is time that makes the difference (37'8% vs 28% at 12 months, 24'6% vs 17% at 24 months). In our trial, during the first 6 months about 6'5% of the patients progressed each month (till reaching 39%, to give 61% PFS at six months). Obviously, the rythm should decrease a bit with time. May be, with luck, we reach something near to 8 months mPFS.
